Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 9/20 | 0.40 |
| ▸ | JAK1 | P23458 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105397 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL388054 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL5751932 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL849908 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL17632152 | 0.81 | USP2 (0.41) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL386890 | 0.80 | SMN1; SMN2 (0.41) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL2887782 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL1118226 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL1973674 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL3105405 | 0.79 | USP2 (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| CN-114728170-B | Compounds active on nuclear receptors | 纽韦卢森公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| EP-4076661-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | disclosed |
| CN-114728170-A | Compounds active on nuclear receptors | 纽韦卢森公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021124279-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885CTSK 3288/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885CTSK 3288/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885CTSK 3288/4885 |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | USP2 99/4885SMN1; SMN2 349/4885CTSK 1616/4885 |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885CTSK 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.